Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Acne
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Acne
    Low-Dose, Drospirenone-Containing Oral Contraceptive Approved in Europe - (DGNews)
    Combination Topical Therapy Effective And Safe for Moderate and Moderate-Severe Acne: Presented at AAD - (DGDispatch)
    Treatment of Mild to Moderate Acne: Presented at AAFP - (DGDispatch)
    Contraceptive Pill Effective Against Adult Acne When Compared With Placebo: Presented at ACOG - (DGDispatch)
    Teens' Stress Levels Linked to Acne Severity - (DGNews)

    News archive

     Recent webcasts/CME - Acne
      What Lies Beneath: Taking a Deeper Look at Acne Patient Care Strategies
      Advances in Dermatological Care: What the Family Physician Needs to Know

      Webcasts/CME archive

       Recent cases - Acne
        Interstitial Pneumonia and Hepatitis Caused by Minocycline
        Minocycline-Induced Hyperpigmentation of the Tongue

        Cases archive
          




        my personal edition > acne > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Tazarotene Gel For Acne Vulgaris Proves Safe And Effective

        A DGReview of :"Successful Treatment of Acne Vulgaris Using a New Method : Results of a Randomized Vehicle-Controlled Trial of Short-Contact Therapy With 0.1% Tazarotene Gel"
        Archives of Dermatology

        04/22/2002
        By David Loshak


        Newly developed short-contact 0.1% tazarotene gel is a safe and effective treatment for acne, minimising local adverse effects.

        To assess the gel's tolerability and effectiveness in treating facial acne, dermatologists at Mount Sinai School of Medicine, New York, United States, conducted a 12-week randomised, masked, vehicle-controlled trial of the tazarotene gel versus a non-medicated gel control.

        Three groups of 33 patients each were randomly assign to receive 0.1% tazarotene gel twice daily, 0.1% tazarotene gel once daily plus vehicle gel once daily, or vehicle gel twice daily. Patients adjusted applications to between 30 seconds and five minutes, as tolerated.

        By week 12, the two tazarotene regimens achieved significantly greater mean percentage reductions in non-inflammatory lesions (41-46 percent) than vehicle gel twice daily (2 percent). The two tazarotene regimens also achieved significantly greater mean percentage reductions in inflammatory lesions (34-38 percent) than vehicle gel twice daily (9 percent).

        In addition, the two tazarotene regimens were superior in terms of the percentage of treatment successes (61-64 percent versus 15 percent with the vehicle gel), and in their reduction of overall disease severity (29-30 percent versus three percent).

        Local adverse effects did not differ significantly between the three groups after the fourth week of the study.
        Archives of Dermatology 2002;138:481-489. "Successful Treatment of Acne Vulgaris Using a New Method : Results of a Randomized Vehicle-Controlled Trial of Short-Contact Therapy With 0.1% Tazarotene Gel"

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send